Harvard Bioscience (HBIO) Q4 2025 earnings summary

Executive summary

• 2025 marked a pivotal year with foundational changes, including comprehensive refinancing, operational reorganization, and leadership enhancements, including a new CEO and permanent CFO.

• Manufacturing consolidation and cost discipline led to improved financial flexibility and a leaner, more efficient organization.

• Strategic focus shifted toward translational science, platform-based innovation, and recurring revenue streams.

• Exited FY25 with a strengthened balance sheet and improved liquidity.

Financial highlights

• Q4 2025 revenue was $23.7M, above guidance midpoint but down from $24.6M in Q4 2024; gross margin reached 59.77%, up 260 bps year-over-year.

• Q4 adjusted EBITDA grew 27% year-over-year to $3.8M; operating income rose to $1.7M from flat last year.

• Full-year 2025 revenue was $86.6M, down from $94.1M, mainly due to tariffs and delayed NIH funding; adjusted EBITDA increased 12.5% to $8.1M.

• GAAP net loss for the year was $1.28 per share, primarily due to a goodwill impairment; adjusted loss per share was $0.02.

• Cash flow from operations improved to $6.7M from $1.4M in 2024; net debt reduced by $1.8M to $31.4M.

Outlook and guidance

• 2026 guidance: revenue growth of 2%-4%, gross margin of 58%-60%, and adjusted EBITDA growth of 6%-10%.

• Q1 2026 expected revenue between $20M-$22M, adjusted gross margin 57%-59%, adjusted EBITDA $1M-$2.2M.

• High margin NPI products like BTX and Mesh MEA expected to grow double digits in 2026.

• Revenue expected to ramp through 2026, supported by NPI and improved NIH funding environment.